Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 6 |
| List of Tables | 6 | 1 |
| List of Figures | 7 | 1 |
| Introduction | 8 | 1 |
| Global Markets Direct Report Coverage | 8 | 1 |
| Liver Failure (Hepatic Insufficiency) Overview | 9 | 1 |
| Therapeutics Development | 10 | 2 |
| Pipeline Products for Liver Failure (Hepatic Insufficiency) Overview | 10 | 1 |
| Pipeline Products for Liver Failure (Hepatic Insufficiency) Comparative Analysis | 11 | 1 |
| Liver Failure (Hepatic Insufficiency) Therapeutics under Development by Companies | 12 | 1 |
| Liver Failure (Hepatic Insufficiency) Therapeutics under Investigation by Universities/Institutes | 13 | 1 |
| Liver Failure (Hepatic Insufficiency) Pipeline Products Glance | 14 | 4 |
| Late Stage Products | 14 | 1 |
| Clinical Stage Products | 15 | 1 |
| Early Stage Products | 16 | 1 |
| Unknown Stage Products | 17 | 1 |
| Liver Failure (Hepatic Insufficiency) Products under Development by Companies | 18 | 1 |
| Liver Failure (Hepatic Insufficiency) Products under Investigation by Universities/Institutes | 19 | 1 |
| Liver Failure (Hepatic Insufficiency) Companies Involved in Therapeutics Development | 20 | 12 |
| Alfact Innovation | 20 | 1 |
| Cell2B S.A. | 21 | 1 |
| Conatus Pharmaceuticals Inc. | 22 | 1 |
| Digna Biotech, S.L. | 23 | 1 |
| Immune Pharmaceuticals Inc. | 24 | 1 |
| Meda AB | 25 | 1 |
| Ocera Therapeutics, Inc. | 26 | 1 |
| PledPharma AB | 27 | 1 |
| Promethera Biosciences S.A. | 28 | 1 |
| Silence Therapeutics Plc | 29 | 1 |
| TGV-Laboratories | 30 | 1 |
| Ventria Bioscience | 31 | 1 |
| Liver Failure (Hepatic Insufficiency) Therapeutics Assessment | 32 | 9 |
| Assessment by Monotherapy Products | 32 | 1 |
| Assessment by Target | 33 | 2 |
| Assessment by Mechanism of Action | 35 | 2 |
| Assessment by Route of Administration | 37 | 2 |
| Assessment by Molecule Type | 39 | 2 |
| Drug Profiles | 41 | 27 |
| ALF-5755 - Drug Profile | 41 | 1 |
| Product Description | 41 | 1 |
| Mechanism of Action | 41 | 1 |
| R&D Progress | 41 | 2 |
| Antisense RNAi Oligonucleotide for Liver Diseases - Drug Profile | 43 | 1 |
| Product Description | 43 | 1 |
| Mechanism of Action | 43 | 1 |
| R&D Progress | 43 | 1 |
| Cardiotrophin-1 - Drug Profile | 44 | 1 |
| Product Description | 44 | 1 |
| Mechanism of Action | 44 | 1 |
| R&D Progress | 44 | 2 |
| Cell Therapy for Liver Failure - Drug Profile | 46 | 1 |
| Product Description | 46 | 1 |
| Mechanism of Action | 46 | 1 |
| R&D Progress | 46 | 1 |
| emricasan - Drug Profile | 47 | 1 |
| Product Description | 47 | 1 |
| Mechanism of Action | 47 | 1 |
| R&D Progress | 47 | 2 |
| F-573 - Drug Profile | 49 | 1 |
| Product Description | 49 | 1 |
| Mechanism of Action | 49 | 1 |
| R&D Progress | 49 | 1 |
| Hep-114 - Drug Profile | 50 | 1 |
| Product Description | 50 | 1 |
| Mechanism of Action | 50 | 1 |
| R&D Progress | 50 | 1 |
| HepaStem - Drug Profile | 51 | 1 |
| Product Description | 51 | 1 |
| Mechanism of Action | 51 | 1 |
| R&D Progress | 51 | 2 |
| ImmuneSafe - Drug Profile | 53 | 1 |
| Product Description | 53 | 1 |
| Mechanism of Action | 53 | 1 |
| R&D Progress | 53 | 2 |
| MTL-CEBPA - Drug Profile | 55 | 1 |
| Product Description | 55 | 1 |
| Mechanism of Action | 55 | 1 |
| R&D Progress | 55 | 1 |
| Oligonucleotide for Liver Failure - Drug Profile | 56 | 1 |
| Product Description | 56 | 1 |
| Mechanism of Action | 56 | 1 |
| R&D Progress | 56 | 1 |
| ornithine phenylacetate - Drug Profile | 57 | 1 |
| Product Description | 57 | 1 |
| Mechanism of Action | 57 | 1 |
| R&D Progress | 57 | 2 |
| PP-100 - Drug Profile | 59 | 1 |
| Product Description | 59 | 1 |
| Mechanism of Action | 59 | 1 |
| R&D Progress | 59 | 1 |
| Recombinant Protein to Inhibit JNK for Liver Failure - Drug Profile | 60 | 1 |
| Product Description | 60 | 1 |
| Mechanism of Action | 60 | 1 |
| R&D Progress | 60 | 1 |
| RNAi Oligonucleotides to Inhibit MAP Kinase 4 for Liver Failure - Drug Profile | 61 | 1 |
| Product Description | 61 | 1 |
| Mechanism of Action | 61 | 1 |
| R&D Progress | 61 | 1 |
| silibinin - Drug Profile | 62 | 1 |
| Product Description | 62 | 1 |
| Mechanism of Action | 62 | 1 |
| R&D Progress | 62 | 1 |
| Small Molecules to Inhibit JNK for Type 2 Diabetes and Liver Failure - Drug Profile | 63 | 1 |
| Product Description | 63 | 1 |
| Mechanism of Action | 63 | 1 |
| R&D Progress | 63 | 1 |
| Stem Cell Therapy for Osteoarthritis, Diabetes Mellitus, Acute Liver Failure and Neurodegenerative Diseases - Drug Profile | 64 | 1 |
| Product Description | 64 | 1 |
| Mechanism of Action | 64 | 1 |
| R&D Progress | 64 | 2 |
| VEN-100 - Drug Profile | 66 | 1 |
| Product Description | 66 | 1 |
| Mechanism of Action | 66 | 1 |
| R&D Progress | 66 | 2 |
| Liver Failure (Hepatic Insufficiency) Recent Pipeline Updates | 68 | 12 |
| Liver Failure (Hepatic Insufficiency) - Dormant Projects | 80 | 1 |
| Liver Failure (Hepatic Insufficiency) Discontinued Products | 81 | 1 |
| Liver Failure (Hepatic Insufficiency) Product Development Milestones | 82 | 9 |
| Featured News &Press Releases | 82 | 1 |
| Nov 19, 2015: Marina Biotech Reports pre-clinical data on its MTL-CEBPA at the 2015 American Association for the Study of Liver Diseases | 82 | 1 |
| Nov 16, 2015: Conatus Pharmaceuticals Announces Poster Presentations at AASLD Annual Meeting | 82 | 1 |
| Oct 05, 2015: Ocera Therapeutics Highlights OCR-002 Data to be Presented at the Annual Meeting of the American Association for the Study of Liver Diseases | 83 | 1 |
| Jan 08, 2015: Conatus Announces Top-Line Results From ACLF and Organ Impairment Clinical Trials of Emricasan | 84 | 2 |
| Jan 05, 2015: Conatus to Report Top-line Results From ACLF and Organ Impairment Clinical Trials of Emricasan | 86 | 1 |
| Nov 02, 2013: Conatus Pharmaceuticals Presents Data Demonstrating Emricasan's Safety Profile at the AASLD Liver Meeting | 86 | 1 |
| Apr 11, 2013: Gene inhibition helps to improve liver regeneration | 87 | 1 |
| Apr 02, 2013: ALF-5755 phase II completion | 88 | 1 |
| Nov 08, 2012: Ocera Therapeutics Enrolls First Patient In Phase IIa Study Of OCR-002 In Treatment Of Patients With Acute Liver Injury | 88 | 1 |
| Aug 03, 2012: MDC Researchers Develop New Approach to Treat Acute Liver Failure | 89 | 2 |
| Appendix | 91 | 2 |
| Methodology | 91 | 1 |
| Coverage | 91 | 1 |
| Secondary Research | 91 | 1 |
| Primary Research | 91 | 1 |
| Expert Panel Validation | 91 | 1 |
| Contact Us | 91 | 1 |
| Disclaimer | 92 | 1 |